Insmed Financial Ratios
NASDAQ: INSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Insmed ratio analysis
Insmed earned a net margin of -210.5% in FY 2025, up from -251.2% a year earlier. Gross margin was 79.7% compared with a median of 76.6% over the prior 7 years. Return on equity reached -172.8%, meaning Insmed generated -1.73 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.73 versus 3.87 the year before, and the current ratio was 3.83. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Insmed financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 58.13 | 31.51 | 14.26 | 10.02 | 16.20 | 19.76 | 14.72 | 116.10 | — | — |
| Price / book | 47.70 | 40.16 | — | 27.95 | 7.44 | 11.78 | 7.67 | 5.48 | 5.75 | 5.30 |
| Gross margin | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | 75.7% | 82.3% | 75.4% | — | — |
| Operating margin | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3,124.9% | — | — |
| Net margin | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3,297.2% | — | — |
| Free cash flow margin | -159.6% | -194.1% | -180.1% | -167.2% | -196.6% | -137.2% | -214.6% | -2,756.1% | — | — |
| Return on equity (ROE) | -172.8% | -320.2% | — | -547.5% | -105.9% | -106.6% | -97.2% | -155.7% | -53.4% | -114.1% |
| Return on assets (ROA) | -56.4% | -45.1% | -56.4% | -29.1% | -35.0% | -36.9% | -34.3% | -53.6% | -41.7% | -74.1% |
| Debt / equity | 0.73 | 3.87 | — | 12.79 | 1.38 | 1.29 | 1.28 | 1.52 | 0.15 | 0.35 |
| Current ratio | 3.83 | 5.45 | 4.12 | 6.69 | 6.19 | 5.24 | 6.51 | 6.51 | 8.72 | 6.02 |
| Revenue growth | 66.7% | 19.2% | 24.4% | 30.2% | 14.6% | 20.5% | 1,287.6% | — | — | — |